Within this category, molecular alterations help to drive WHO grade II and III diagnoses, and diagnostic entities include diffuse astrocytoma designated as IDH-mutant or IDH-wildtype; anaplastic astrocytoma designated as IDH-mutant or IDH-wildtype; Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted; and anaplastic oligodendroglioma, IDH-mutant, and 1p/19q-codeleted [23]. The gene discussed is IDH2; the disease is anaplastic astrocytoma.